Cychlorphine Urine Testing: Panel Coverage and Detection-Time Limits

By Forensic Toxicology Working Group Members · September 25, 2026

Cychlorphine may be encountered when a person believes a street product contains fentanyl or a nitazene. A September 2026 Estonian study compares those expectations with urine toxicology. Its practical contribution is evidence of an identification gap; it does not validate a time-since-use calculation or an impairment threshold.

Study design and principal result

Abel-Ollo and colleagues studied people who inject drugs in Kohtla-Järve. Of 350 survey participants, 112 voluntarily supplied urine and completed a questionnaire covering the preceding seven days. LC-Q-TOF-MS detected cychlorphine in 22 of 112 specimens, or 19.6%. The paper was published September 22, 2026.

The 32% participation rate in the toxicology substudy and the single-city sampling frame limit generalization. The observed positivity is neither a national prevalence estimate nor a measurement of what proportion of all street products contained cychlorphine. The authors interpret the discordance as evidence of misidentification and possible supply substitution.

Cychlorphine is outside the nitazene family

Cychlorphine, also called N-propionitrile chlorphine, belongs to the benzimidazolone or orphine group. A method targeting nitazenes must not be assumed to cover it. Laboratory information systems and spectral libraries should reconcile spelling variants, including cychlorophine and N-propionitrile chlorophine, with the actual chemical identity.

Why the reported times are not a detection window

The study abstract reports a mean of 17.1 hours since self-reported use among positive findings and a mean of 47.6 hours for negative findings. These are observational group summaries. They are not a half-life, a latest possible positive result, or proof that a negative specimen excludes use within a specified interval.

Controlled administration with known dose and serial sampling would answer a different question. Here, uncertainty about product identity compounds uncertainty about reported timing. An individual’s urine concentration, repeated exposures, dose, metabolism, and the method’s reporting limit could affect the result.

Laboratory implementation questions

Is cychlorphine explicitly covered by the validated method and report?
Are retention time and diagnostic fragments compared with a suitable reference standard?
What are the matrix-specific detection and reporting limits?
Which metabolites are included, and how strong is their identification?
Are extraction, matrix effects, carryover, interference, and stability adequately characterized?
Can retained HRMS data be reprocessed, and did the original acquisition capture sufficient diagnostic information?

The accessible abstract identifies LC-Q-TOF-MS but does not establish these performance characteristics. Retrospective data review is an investigative step; a library hit still requires evaluation under the laboratory’s identification criteria.

Earlier analytical work explains the practical problem

A January 12, 2026 study by Dugues and colleagues described drug-material peaks initially unidentified because matching library spectra were unavailable. LC-HRMS and NMR supported structural identification, with targeted LC-MS/MS quantification. This older work explains why a current negative library search can reflect incomplete coverage.

Research papers and technical resource

Abel-Ollo et al. Discordance between self-reported and detected synthetic opioids reveals cychlorphine emergence among people who inject drugs in Estonia. September 22, 2026. Cross-sectional urine substudy; abstract-level review.
Dugues et al. Multi-analytical identification of cychlorphine and methiodone in drug seizures. January 12, 2026. Older analytical background; drug materials rather than human impairment evidence.
CFSRE N-Propionitrile Chlorphine technical entry: nomenclature and analytical information.